Scandion Oncology receives approvals for next parts of the CORIST trial
The development of SCO-101 will continue as planned with expansion of the CORIST trial expected to commence during the third quarter of 2022.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has now received approvals from authorities and ethical committees in Denmark and Germany for the next parts of the ongoing CORIST phase II-trial. The trial studies Scandion’s lead compound SCO-101 as a combination treatment in patients with metastatic colorectal cancer (mCRC). Thus, the